Veracyte (VCYT) to Release Earnings on Tuesday

Veracyte (NASDAQ:VCYT) will likely be issuing its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect the company to announce earnings of $0.34 per share and revenue of $130.1440 million for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

Veracyte (NASDAQ:VCYT) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.41 by $0.12. Veracyte had a net margin of 12.83% and a return on equity of 8.05%. The company had revenue of $140.64 million during the quarter, compared to the consensus estimate of $135.79 million. During the same quarter last year, the firm posted $0.06 EPS. The company’s quarterly revenue was up 18.5% on a year-over-year basis. On average, analysts expect Veracyte to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Veracyte Trading Down 2.2%

Shares of VCYT traded down $0.73 during trading hours on Tuesday, reaching $33.12. The stock had a trading volume of 100,300 shares, compared to its average volume of 864,243. Veracyte has a 12 month low of $22.61 and a 12 month high of $50.71. The firm has a 50-day simple moving average of $33.60 and a 200 day simple moving average of $38.21. The company has a market capitalization of $2.64 billion, a price-to-earnings ratio of 39.93 and a beta of 1.96.

Analyst Ratings Changes

A number of equities analysts recently issued reports on VCYT shares. Zacks Research cut Veracyte from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 12th. Jefferies Financial Group started coverage on Veracyte in a report on Monday, April 13th. They issued a “buy” rating and a $45.00 target price on the stock. Canaccord Genuity Group cut their target price on Veracyte from $43.00 to $40.00 and set a “hold” rating on the stock in a report on Monday, April 20th. Morgan Stanley cut their target price on Veracyte from $48.00 to $37.00 and set an “underweight” rating on the stock in a report on Thursday, March 5th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $48.00 target price on shares of Veracyte in a report on Wednesday, April 1st. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $43.83.

Insider Buying and Selling

In other Veracyte news, CFO Rebecca Chambers sold 18,341 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $36.14, for a total transaction of $662,843.74. Following the transaction, the chief financial officer directly owned 131,196 shares in the company, valued at approximately $4,741,423.44. This trade represents a 12.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John Leite sold 5,260 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $35.19, for a total value of $185,099.40. Following the transaction, the insider owned 107,580 shares in the company, valued at approximately $3,785,740.20. This trade represents a 4.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 75,782 shares of company stock valued at $2,722,097 in the last 90 days. Insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Veracyte

Several large investors have recently bought and sold shares of VCYT. California State Teachers Retirement System raised its stake in shares of Veracyte by 0.8% during the 2nd quarter. California State Teachers Retirement System now owns 71,095 shares of the biotechnology company’s stock worth $1,922,000 after purchasing an additional 566 shares during the period. O Shaughnessy Asset Management LLC raised its stake in shares of Veracyte by 7.9% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 7,894 shares of the biotechnology company’s stock worth $332,000 after purchasing an additional 576 shares during the period. Smartleaf Asset Management LLC raised its stake in shares of Veracyte by 159.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,104 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 679 shares during the period. Xponance LLC raised its stake in shares of Veracyte by 12.1% during the 4th quarter. Xponance LLC now owns 6,871 shares of the biotechnology company’s stock worth $289,000 after purchasing an additional 741 shares during the period. Finally, Osaic Holdings Inc. raised its stake in shares of Veracyte by 21.0% during the 4th quarter. Osaic Holdings Inc. now owns 4,713 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 817 shares during the period.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.